Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com
Royalty Pharma plc (NASDAQ: RPRX) delivered a strong performance in the third quarter of 2024, with significant increases in Portfolio and Royalty Receipts and a raised full-year financial outlook. The company’s strategic acquisitions and share repurchases underscore its commitment to growth and shareholder value. Royalty Pharma’s management expressed confidence in the company’s trajectory, supported by … Read more